Quantitative assessment of olfactory dysfunction accurately detects asymptomatic COVID-19 carriers.


Journal

EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 07 08 2020
revised: 16 09 2020
accepted: 17 09 2020
pubmed: 22 10 2020
medline: 22 10 2020
entrez: 21 10 2020
Statut: ppublish

Résumé

COVID-19 threatens the global community because a large fraction of infected people are asymptomatic, yet can effectively transmit SARS-CoV-2. Finding and isolating these silent carriers is a crucial step in confining the spread of the disease. A sudden loss of the sense of smell has been self-reported by COVID-19 patients across different countries, consistent with expression of the molecular factors mediating SARS-CoV-2 uptake into human olfactory epithelial supporting cells. However, precise quantification of olfactory loss in asymptomatic COVID-19 carriers is missing to date. To quantify olfactory functions in asymptomatic COVID-19 patients, we designed an olfactory-action meter that determines detectability indices at different odor concentrations and an olfactory matching accuracy score using monomolecular odors. The optimization of test parameters allowed us to reliably and accurately assess olfactory deficits in a patient within 20 minutes. Measurement of detection indices at low concentrations revealed a 50% reduction in asymptomatic COVID-19 carriers. Further, patients with better detection scores showed significantly reduced olfactory matching accuracies compared to normal healthy subjects. Our quantification of olfactory loss, considering all parameters, identified 82% of the asymptomatic SARS-CoV-2 carriers with olfactory deficits. However, on subjective evaluation, only 15% of the patients noticed a compromised ability to smell. Compromised olfactory fitness can serve as a strong basis for identifying asymptomatic COVID-19 patients. Detailed design specifications and protocols provided here should enable the development of a sensitive, fast, and economical screening strategy that can be administered to large populations to prevent the rapid spread of COVID-19. This work was supported by the DBT - Wellcome Trust India Alliance intermediate grant (IA/I/14/1/501,306 to N.A.) and UGC NET Fellowship (A.B.). All the funding sources played no roles in the study.

Sections du résumé

BACKGROUND BACKGROUND
COVID-19 threatens the global community because a large fraction of infected people are asymptomatic, yet can effectively transmit SARS-CoV-2. Finding and isolating these silent carriers is a crucial step in confining the spread of the disease. A sudden loss of the sense of smell has been self-reported by COVID-19 patients across different countries, consistent with expression of the molecular factors mediating SARS-CoV-2 uptake into human olfactory epithelial supporting cells. However, precise quantification of olfactory loss in asymptomatic COVID-19 carriers is missing to date.
METHODS METHODS
To quantify olfactory functions in asymptomatic COVID-19 patients, we designed an olfactory-action meter that determines detectability indices at different odor concentrations and an olfactory matching accuracy score using monomolecular odors. The optimization of test parameters allowed us to reliably and accurately assess olfactory deficits in a patient within 20 minutes.
FINDINGS RESULTS
Measurement of detection indices at low concentrations revealed a 50% reduction in asymptomatic COVID-19 carriers. Further, patients with better detection scores showed significantly reduced olfactory matching accuracies compared to normal healthy subjects. Our quantification of olfactory loss, considering all parameters, identified 82% of the asymptomatic SARS-CoV-2 carriers with olfactory deficits. However, on subjective evaluation, only 15% of the patients noticed a compromised ability to smell.
INTERPRETATION CONCLUSIONS
Compromised olfactory fitness can serve as a strong basis for identifying asymptomatic COVID-19 patients. Detailed design specifications and protocols provided here should enable the development of a sensitive, fast, and economical screening strategy that can be administered to large populations to prevent the rapid spread of COVID-19.
FUNDING BACKGROUND
This work was supported by the DBT - Wellcome Trust India Alliance intermediate grant (IA/I/14/1/501,306 to N.A.) and UGC NET Fellowship (A.B.). All the funding sources played no roles in the study.

Identifiants

pubmed: 33083773
doi: 10.1016/j.eclinm.2020.100575
pii: S2589-5370(20)30319-9
pmc: PMC7562772
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100575

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : DBT-Wellcome Trust India Alliance
ID : IA/I/14/1/501306
Pays : India

Informations de copyright

© 2020 The Author(s).

Déclaration de conflit d'intérêts

Indian Institute of Science Education and Research (IISER), Pune has submitted a provisional patent application for the olfactory-action meter with Dr. Nixon M. Abraham as the inventor (Patent application No: IN 202,021,035,482 dated 18/08/2020). Other authors declare that they have no known competing financial interest. All authors declare that they have no known personal relationships that could have appeared to influence the work reported in this paper. This paper has never been published elsewhere.

Références

Clin Infect Dis. 2020 Jul 28;71(15):889-890
pubmed: 32215618
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
Head Neck. 2020 Jun;42(6):1252-1258
pubmed: 32342566
EClinicalMedicine. 2020 Aug;25:100484
pubmed: 32838240
Eur Arch Otorhinolaryngol. 2021 Jan;278(1):247-255
pubmed: 32749606
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261
pubmed: 32253535
Rhinology. 2020 Jun 1;58(3):295-298
pubmed: 32277751
J Comp Neurol. 2005 Mar 7;483(2):154-63
pubmed: 15678478
Chem Senses. 1997 Feb;22(1):39-52
pubmed: 9056084
Med J Islam Repub Iran. 2020 Jun 15;34:62
pubmed: 32974228
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
JAMA Otolaryngol Head Neck Surg. 2020 Jul 1;146(7):674-675
pubmed: 32267483
Laryngoscope. 2020 Sep;130(9):E506
pubmed: 32603478
Cell. 1991 Apr 5;65(1):175-87
pubmed: 1840504
ACS Chem Neurosci. 2020 Jun 3;11(11):1555-1562
pubmed: 32379417
Lancet. 2020 Jun 20;395(10241):e107-e108
pubmed: 32505221
Nat Rev Neurol. 2020 Nov;16(11):636-644
pubmed: 32839585
JAMA. 2020 Jun 23;323(24):2512-2514
pubmed: 32432682
Neuron. 2006 Feb 2;49(3):467-79
pubmed: 16446149
Int Forum Allergy Rhinol. 2020 Aug;10(8):944-950
pubmed: 32301284
Nat Neurosci. 2011 Sep 25;14(11):1455-61
pubmed: 21946326
ORL J Otorhinolaryngol Relat Spec. 2020;82(4):175-180
pubmed: 32526759
Nat Methods. 2008 May;5(5):425-9
pubmed: 18376403
Hum Genomics. 2008 Sep;3(1):87-97
pubmed: 19129093
Chem Senses. 2020 May 22;:
pubmed: 32441744
Nat Neurosci. 2020 Mar;23(3):323-326
pubmed: 32066986
Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):19959-64
pubmed: 23169632
ACS Chem Neurosci. 2020 Jul 1;11(13):1909-1913
pubmed: 32525657
BMC Med Res Methodol. 2013 Jul 16;13:92
pubmed: 23855337
Head Neck. 2020 Jul;42(7):1570-1576
pubmed: 32357379
N Engl J Med. 2020 Jun 4;382(23):2268-2270
pubmed: 32294339
BMJ. 2020 Apr 2;369:m1375
pubmed: 32241884
Auris Nasus Larynx. 2020 Aug;47(4):565-573
pubmed: 32553562
Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2584-9
pubmed: 14983052
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Nat Med. 2020 Jul;26(7):1037-1040
pubmed: 32393804
Sci Adv. 2020 Jul 31;6(31):
pubmed: 32937591
J Intern Med. 2020 Sep;288(3):335-344
pubmed: 32352202
Neuron. 2020 Jul 22;107(2):219-233
pubmed: 32640192
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
J Physiol. 2005 Feb 1;562(Pt 3):785-99
pubmed: 15611020

Auteurs

Anindya S Bhattacharjee (AS)

Indian Institute of Science Education and Research (IISER), Pune, Maharashtra, 411008, India.

Samir V Joshi (SV)

Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals (BJGMC & SGH), Pune, Maharashtra, 411001, India.

Shilpa Naik (S)

Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals (BJGMC & SGH), Pune, Maharashtra, 411001, India.

Shashikala Sangle (S)

Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals (BJGMC & SGH), Pune, Maharashtra, 411001, India.

Nixon M Abraham (NM)

Indian Institute of Science Education and Research (IISER), Pune, Maharashtra, 411008, India.

Classifications MeSH